Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. LATS2 - Wikipedia
LATS2 - Wikipedia
From Wikipedia, the free encyclopedia
Protein-coding gene in the species Homo sapiens
LATS2
Available structures
PDBOrtholog search: PDBe RCSB
List of PDB id codes

4ZRI

Identifiers
AliasesLATS2, KPM, large tumor suppressor kinase 2
External IDsOMIM: 604861; MGI: 1354386; HomoloGene: 56678; GeneCards: LATS2; OMA:LATS2 - orthologs
Gene location (Human)
Chromosome 13 (human)
Chr.Chromosome 13 (human)[1]
Chromosome 13 (human)
Genomic location for LATS2
Genomic location for LATS2
Band13q12.11Start20,973,036 bp[1]
End21,061,586 bp[1]
Gene location (Mouse)
Chromosome 14 (mouse)
Chr.Chromosome 14 (mouse)[2]
Chromosome 14 (mouse)
Genomic location for LATS2
Genomic location for LATS2
Band14|14 C3Start57,927,119 bp[2]
End57,995,845 bp[2]
RNA expression pattern
Bgee
HumanMouse (ortholog)
Top expressed in
  • pancreatic epithelial cell

  • myocardium of left ventricle

  • visceral pleura

  • parietal pleura

  • tibialis anterior muscle

  • tibia

  • germinal epithelium

  • cardiac muscle tissue of right atrium

  • lower lobe of lung

  • amniotic fluid
Top expressed in
  • ascending aorta

  • aortic valve

  • external carotid artery

  • sciatic nerve

  • cardiac muscle tissue of left ventricle

  • internal carotid artery

  • spermatid

  • left lung lobe

  • plantaris muscle

  • carotid body
More reference expression data
BioGPS
More reference expression data
Gene ontology
Molecular function
  • transferase activity
  • nucleotide binding
  • protein kinase activity
  • metal ion binding
  • kinase activity
  • protein binding
  • ATP binding
  • protein serine/threonine kinase activity
Cellular component
  • spindle pole
  • microtubule organizing center
  • cytoskeleton
  • nucleus
  • cytoplasm
  • cytosol
Biological process
  • intracellular signal transduction
  • phosphorylation
  • negative regulation of cyclin-dependent protein serine/threonine kinase activity
  • cell division
  • protein phosphorylation
  • peptidyl-serine phosphorylation
  • hormone-mediated signaling pathway
  • positive regulation of apoptotic process
  • cell cycle
  • G1/S transition of mitotic cell cycle
  • hippo signaling
  • regulation of organ growth
  • negative regulation of canonical Wnt signaling pathway
  • inner cell mass cell fate commitment
  • inner cell mass cellular morphogenesis
  • keratinocyte differentiation
Sources:Amigo / QuickGO
Orthologs
SpeciesHumanMouse
Entrez

26524

50523

Ensembl

ENSG00000150457

ENSMUSG00000021959

UniProt

Q9NRM7

Q7TSJ6

RefSeq (mRNA)

NM_014572

NM_015771
NM_153382

RefSeq (protein)

NP_055387

NP_056586
NP_700431

Location (UCSC)Chr 13: 20.97 – 21.06 MbChr 14: 57.93 – 58 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Large tumor suppressor kinase 2 (LATS2) is an enzyme that in humans is encoded by the LATS2 gene.[5][6]

This gene encodes a serine/threonine protein kinase belonging to the LATS tumor suppressor family and participates in the Hippo signaling pathway where it inactivates the effector proteins, YAP and WWTR1 (TAZ). The protein localizes to centrosomes during interphase and early and late metaphase. It interacts with the centrosomal proteins aurora-A and ajuba and is required for accumulation of gamma-tubulin and spindle formation at the onset of mitosis. It also interacts with a negative regulator of p53 and may function in a positive feedback loop with p53 that responds to cytoskeleton damage. Additionally, it can function as a corepressor of androgen-responsive gene expression.[6]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000150457 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000021959 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Yabuta N, Fujii T, Copeland NG, Gilbert DJ, Jenkins NA, Nishiguchi H, Endo Y, Toji S, Tanaka H, Nishimune Y, Nojima H (Apr 2000). "Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts". Genomics. 63 (2): 263–70. doi:10.1006/geno.1999.6065. PMID 10673337.
  6. ^ a b "Entrez Gene: LATS2 LATS, large tumor suppressor, homolog 2 (Drosophila)".

Further reading

[edit]
  • Hori T, Takaori-Kondo A, Kamikubo Y, Uchiyama T (2000). "Molecular cloning of a novel human protein kinase, kpm, that is homologous to warts/lats, a Drosophila tumor suppressor". Oncogene. 19 (27): 3101–9. doi:10.1038/sj.onc.1203659. PMID 10871863.
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. Bibcode:2002PNAS...9916899M. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
  • Li Y, Pei J, Xia H, et al. (2003). "Lats2, a putative tumor suppressor, inhibits G1/S transition". Oncogene. 22 (28): 4398–405. doi:10.1038/sj.onc.1206603. PMID 12853976.
  • Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
  • Powzaniuk M, McElwee-Witmer S, Vogel RL, et al. (2005). "The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor". Mol. Endocrinol. 18 (8): 2011–23. doi:10.1210/me.2004-0065. PMID 15131260.
  • Toji S, Yabuta N, Hosomi T, et al. (2005). "The centrosomal protein Lats2 is a phosphorylation target of Aurora-A kinase". Genes Cells. 9 (5): 383–97. doi:10.1111/j.1356-9597.2004.00732.x. PMID 15147269.
  • Ke H, Pei J, Ni Z, et al. (2004). "Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L)". Exp. Cell Res. 298 (2): 329–38. doi:10.1016/j.yexcr.2004.04.031. PMID 15265683.
  • Chan EH, Nousiainen M, Chalamalasetty RB, et al. (2005). "The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1". Oncogene. 24 (12): 2076–86. doi:10.1038/sj.onc.1208445. PMID 15688006. S2CID 27285160.
  • Takahashi Y, Miyoshi Y, Takahata C, et al. (2005). "Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers". Clin. Cancer Res. 11 (4): 1380–5. doi:10.1158/1078-0432.CCR-04-1773. PMID 15746036.
  • Abe Y, Ohsugi M, Haraguchi K, et al. (2006). "LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and spindle organization during mitosis". FEBS Lett. 580 (3): 782–8. Bibcode:2006FEBSL.580..782A. doi:10.1016/j.febslet.2005.12.096. PMID 16413547.
  • Voorhoeve PM, le Sage C, Schrier M, et al. (2006). "A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors". Cell. 124 (6): 1169–81. doi:10.1016/j.cell.2006.02.037. PMID 16564011.
  • Aylon Y, Michael D, Shmueli A, et al. (2007). "A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization". Genes Dev. 20 (19): 2687–700. doi:10.1101/gad.1447006. PMC 1578695. PMID 17015431.
  • Jiang Z, Li X, Hu J, et al. (2007). "Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma". Neurosci. Res. 56 (4): 450–8. doi:10.1016/j.neures.2006.09.006. PMID 17049657. S2CID 22763208.
  • v
  • t
  • e
Kinases: Serine/threonine-specific protein kinases (EC 2.7.11-12)
Serine/threonine-specific protein kinases (EC 2.7.11.1-EC 2.7.11.20)
Non-specific serine/threonine protein kinases (EC 2.7.11.1)
  • LATS1
  • LATS2
  • MAST1
  • MAST2
  • STK38
  • STK38L
  • CIT
  • ROCK1
  • SGK
  • SGK2
  • SGK3
  • Protein kinase B
    • AKT1
    • AKT2
    • AKT3
  • Ataxia telangiectasia mutated
  • mTOR
  • EIF-2 kinases
    • PKR
    • HRI
    • EIF2AK3
    • EIF2AK4
  • Wee1
    • WEE1
Pyruvate dehydrogenase kinase (EC 2.7.11.2)
  • PDK1
  • PDK2
  • PDK3
  • PDK4
Dephospho-(reductase kinase) kinase (EC 2.7.11.3)
  • AMP-activated protein kinase α
    • PRKAA1
    • PRKAA2
  • β
    • PRKAB1
    • PRKAB2
  • γ
    • PRKAG1
    • PRKAG2
    • PRKAG3
3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring) kinase (EC 2.7.11.4)
  • BCKDK
  • BCKDHA
  • BCKDHB
(isocitrate dehydrogenase (NADP+)) kinase (EC 2.7.11.5)
  • IDH2
  • IDH3A
  • IDH3B
  • IDH3G
(tyrosine 3-monooxygenase) kinase (EC 2.7.11.6)
  • STK4
Myosin-heavy-chain kinase (EC 2.7.11.7)
  • Aurora kinase
    • Aurora A kinase
    • Aurora B kinase
    • Aurora C kinase
Fas-activated serine/threonine kinase (EC 2.7.11.8)
  • FASTK
  • STK10
Goodpasture-antigen-binding protein kinase (EC 2.7.11.9)
  • -
IκB kinase (EC 2.7.11.10)
  • CHUK
  • IKK2
  • TBK1
  • IKBKE
  • IKBKG
  • IKBKAP
cAMP-dependent protein kinase (EC 2.7.11.11)
  • Protein kinase A
  • PRKACG
  • PRKACB
  • PRKACA
  • PRKY
cGMP-dependent protein kinase (EC 2.7.11.12)
  • Protein kinase G
  • PRKG1
Protein kinase C (EC 2.7.11.13)
  • Protein kinase C
  • Protein kinase Cζ
  • PKC alpha
  • PRKCB1
  • PRKCD
  • PRKCE
  • PRKCH
  • PRKCG
  • PRKCI
  • PRKCQ
  • Protein kinase N1
  • PKN2
  • PKN3
Rhodopsin kinase (EC 2.7.11.14)
  • Rhodopsin kinase
Beta adrenergic receptor kinase (EC 2.7.11.15)
  • Beta adrenergic receptor kinase
  • Beta adrenergic receptor kinase-2
G-protein coupled receptor kinases (EC 2.7.11.16)
  • GRK4
  • GRK5
  • GRK6
Ca2+/calmodulin-dependent (EC 2.7.11.17)
  • BRSK2
  • CAMK1
  • CAMK1A
  • CAMK1B
  • CAMK1D
  • CAMK1G
  • CAMK2
  • CAMK2A
  • CAMK2B
  • CAMK2D
  • CAMK2G
  • CAMK4
  • MLCK
  • CASK
  • CHEK1
  • CHEK2
  • DAPK1
  • DAPK2
  • DAPK3
  • STK11
  • MAPKAPK2
  • MAPKAPK3
  • MAPKAPK5
  • MARK1
  • MARK2
  • MARK3
  • MARK4
  • MELK
  • MKNK1
  • MKNK2
  • NUAK1
  • NUAK2
  • OBSCN
  • PASK
  • PHKG1
  • PHKG2
  • PIM1
  • PIM2
  • PKD1
  • PRKD2
  • PRKD3
  • PSKH1
  • SNF1LK2
  • KIAA0999
  • STK40
  • SNF1LK
  • SNRK
  • SPEG
  • TSSK2
  • Kalirin
  • TRIB1
  • TRIB2
  • TRIB3
  • TRIO
  • Titin
  • DCLK1
Myosin light-chain kinase (EC 2.7.11.18)
  • MYLK
  • MYLK2
  • MYLK3
  • MYLK4
Phosphorylase kinase (EC 2.7.11.19)
  • PHKA1
  • PHKA2
  • PHKB
  • PHKG1
  • PHKG2
Elongation factor 2 kinase (EC 2.7.11.20)
  • EEF2K
  • STK19
Polo kinase (EC 2.7.11.21)
  • PLK1
  • PLK2
  • PLK3
  • PLK4
Serine/threonine-specific protein kinases (EC 2.7.11.21-EC 2.7.11.30)
Polo kinase (EC 2.7.11.21)
  • PLK1
  • PLK2
  • PLK3
  • PLK4
Cyclin-dependent kinase (EC 2.7.11.22)
  • CDK1
  • CDK2
  • CDKL2
  • CDK3
  • CDK4
  • CDK5
  • CDKL5
  • CDK6
  • CDK7
  • CDK8
  • CDK9
  • CDK10
  • CDK12
  • CDC2L5
  • PCTK1
  • PCTK2
  • PCTK3
  • PFTK1
  • CDC2L1
(RNA-polymerase)-subunit kinase (EC 2.7.11.23)
  • RPS6KA5
  • RPS6KA4
  • P70S6 kinase
  • P70-S6 Kinase 1
  • RPS6KB2
  • RPS6KA2
  • RPS6KA3
  • RPS6KA1
  • RPS6KC1
Mitogen-activated protein kinase (EC 2.7.11.24)
  • Extracellular signal-regulated
    • MAPK1
    • MAPK3
    • MAPK4
    • MAPK6
    • MAPK7
    • MAPK12
    • MAPK15
  • C-Jun N-terminal
    • MAPK8
    • MAPK9
    • MAPK10
  • P38 mitogen-activated protein
    • MAPK11
    • MAPK13
    • MAPK14
MAP3K (EC 2.7.11.25)
  • MAP kinase kinase kinases
    • MAP3K1
    • MAP3K2
    • MAP3K3
    • MAP3K4
    • MAP3K5
    • MAP3K6
    • MAP3K7
    • MAP3K8
  • RAFs
    • ARAF
    • BRAF
    • KSR1
    • KSR2
  • MLKs
    • MAP3K12
    • MAP3K13
    • MAP3K9
    • MAP3K10
    • MAP3K11
    • MAP3K7
    • ZAK
  • CDC7
  • MAP3K14
Tau-protein kinase (EC 2.7.11.26)
  • TPK1
  • TTK
  • GSK-3
(acetyl-CoA carboxylase) kinase (EC 2.7.11.27)
  • -
Tropomyosin kinase (EC 2.7.11.28)
  • -
Low-density-lipoprotein receptor kinase (EC 2.7.11.29)
  • -
Receptor protein serine/threonine kinase (EC 2.7.11.30)
  • Bone morphogenetic protein receptors
    • BMPR1
    • BMPR1A
    • BMPR1B
    • BMPR2
  • ACVR1
  • ACVR1B
  • ACVR1C
  • ACVR2A
  • ACVR2B
  • ACVRL1
  • Anti-Müllerian hormone receptor
Dual-specificity kinases (EC 2.7.12)
MAP2K
  • MAP2K1
  • MAP2K2
  • MAP2K3
  • MAP2K4
  • MAP2K5
  • MAP2K6
  • MAP2K7
  • v
  • t
  • e
Enzymes
Activity
  • Active site
  • Binding site
  • Catalytic triad
  • Oxyanion hole
  • Enzyme promiscuity
  • Diffusion-limited enzyme
  • Cofactor
  • Enzyme catalysis
Regulation
  • Allosteric regulation
  • Cooperativity
  • Enzyme inhibitor
  • Enzyme activator
Classification
  • EC number
  • Enzyme superfamily
  • Enzyme family
  • List of enzymes
Kinetics
  • Enzyme kinetics
  • Eadie–Hofstee diagram
  • Hanes–Woolf plot
  • Lineweaver–Burk plot
  • Michaelis–Menten kinetics
Types
  • EC1 Oxidoreductases (list)
  • EC2 Transferases (list)
  • EC3 Hydrolases (list)
  • EC4 Lyases (list)
  • EC5 Isomerases (list)
  • EC6 Ligases (list)
  • EC7 Translocases (list)
Portal:
  • icon Biology


Stub icon

This article on a gene on human chromosome 13 is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=LATS2&oldid=1328789907"
Categories:
  • Genes on human chromosome 13
  • EC 2.7.11
  • Human chromosome 13 gene stubs
Hidden categories:
  • Articles with short description
  • Short description matches Wikidata
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id